What Happened

On June 16, 2026, PsyCan, the trade association representing Canada’s legally operating medical psychedelics sector, welcomed the introduction of Bill C-286, a private member’s bill designed to create a clearer regulated pathway for medical access to psilocybin and psilocin. The legislation was introduced by MP Corey Tochor, the Member of Parliament for Saskatoon—University, and is informally known as "Thomas’ Bill." The bill seeks to amend the Controlled Drugs and Substances Act and the Food and Drugs Act to remove psilocybin and psilocin from the restricted-drug category and place them within an existing controlled-drug medical framework. A key provision of the bill would require Health Canada to grant priority review status to new drug submissions involving psilocybin, psilocin, their salts, or substantially similar compounds. The legislative effort is championed by Austin Miller, President of Bluestem and Chair of PsyCan’s Board of Directors, who supports the move to modernize Canada’s approach to medical psilocybin access while preserving Health Canada’s evidence-based drug review process. The bill aims to replace the current unpredictable system with a faster, more predictable regulated pathway for medical access without bypassing Health Canada’s drug-review process entirely.

Why It Matters

The introduction of Bill C-286 addresses a critical gap in Canada's healthcare system where patients with serious mental health conditions, addiction, trauma, and end-of-life distress are forced to rely on a slow and bureaucratic Special Access Program (SAP). Since 2022, Health Canada’s SAP has allowed case-by-case, practitioner-led requests for psilocybin and MDMA, but approvals have dropped dramatically, with only half as many approvals in 2025 compared to 2024. Timelines on SAP decisions have been growing dramatically, creating significant barriers for patients who need timely access to these therapies. Without a clearer regulated pathway, Canada risks falling behind peer jurisdictions like the United States and Australia, which are actively building frameworks for psychedelic therapies. The bill represents a shift from ad-hoc exemptions to a structured regulatory environment that could legitimize and expand access to psychedelic-assisted therapies for Canadians suffering from chronic mental health conditions.

Local Vancouver / Burnaby Context

While the legislative action is federal and centered in Ottawa, the implications for British Columbia are significant given the province's progressive stance on mental health and its growing interest in alternative therapies. Burnaby and Vancouver have seen increasing advocacy for mental health innovation, and the potential legalization of medical psilocybin could influence local healthcare providers and clinics to prepare for future integration of these treatments. The case of Thomas Hartle, a Saskatchewan father who became the first Canadian to receive a legal exemption for psilocybin therapy in 2020, highlights the national urgency that transcends provincial borders. His story, involving bureaucratic delays that persisted even as he fought stage IV colon cancer, has become a focal point for policymakers across Canada, including in BC, where mental health crises are a pressing public health concern. The shift toward a regulated pathway could also impact local research institutions and medical practitioners in the Greater Vancouver area who are monitoring the landscape for opportunities to participate in clinical trials or future licensed clinics. As the national dialogue evolves, local stakeholders in Burnaby and Vancouver are likely to engage with the broader conversation on how to balance compassionate access with rigorous safety standards.